Rivaroxaban, Most Innovative Drug

Anti-clotting drug Rivaroxaban was awarded as the most innovative drugs in the International Prix Galien 2010. Bayer Schering Pharma Drug production is set aside five competitors, including AstraZeneca's Iressa and Erbitux made from Merck Serono. Previous Rivaroxaban was awarded the Prix Galien was also at the national level in Belgium, France and Switzerland.

Prix Gallen Award gives awards for outstanding achievement in improving health through innovative medicine and is considered equivalent to the Nobel prize in the field of biopharmaceutical research. Prix Galien International Award Committee in 2010 consisted of the winners of the Nobel Prize, led by Gerald Weissmann, MD, Professor of Rheumatology and Director of the Biotechnology Study Center, Faculty of Medicine at the University of New York.

"We are very pleased to receive this award and honored for
worldwide recognition of this committee. Given the Prix Galien International Award for Best Pharmaceutical Agent underscores our efforts to innovation which is the focus character of our company ", commented Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG through a press release.

Rivaroxaban is a new oral anticoagulant found in Bayer Schering Pharma Wuppertal laboratories in Germany, and was developed jointly between Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, LLC

In clinical studies, Rivaroxaban has consistently shown superior efficacy compared with enoxaparin in the prevention of blood clots in veins (VTE) in adult patients who runs the hip joint replacement surgery or knee.

This medicine may work faster with a predictable dose response and with a high bioavailability, is not required supervision on blood coagulation, and also with limited potential to interact with food and medicine.

Rivaroxaban marketed under the trade name Xarelto ® for the prevention of VTE in adult patients who runs the hip joint replacement surgery or knee, and this drug is the first oral anti-coagulants that have consistently demonstrated superior efficacy compared with enoxaparin for this indication.

Rixaroxaban been approved in more than 100 countries around the world and has been launched successfully in over 75 countries. Clinical trial program that supports Rivaroxaban has made many of these drugs into oral drugs Factor Xa directly the most studied in the world today.

Over 65,000 patients involved in clinical development programs Rivaroxaban, which evaluates the product for the prevention and treatment for a wide range of disorders of acute and chronic blood clots, including stroke prevention in patients with atrial fibrillation, secondary prevention of acute coronary syndrome, and prevention of VTE in patients that must be treated in hospital.

Prix Galien Award 2010 will also be given to Firazyr (icatibant) manufactured by Shire Pharmaceuticals for the category of Orphan Drug for the treatment of hereditary angioedema disease in adults. This hereditary disease is an immune system disorder, which causes tissue swelling abruptly.